A Phase 3 interventional study of Faster-acting insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-31.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 60th largest by enrollment, is one of 7 that started in 2013, is one of 24 in phase 3, and was the 49th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Defymed · Sites in France
Ages 18+
By country, each count listing its studies:
Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 3 · Phase 3 26 · Phase 4 24
First in 1989; this study’s year is marked. 7 started in 2013.
This study's enrollment of 37 is close to the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 87 interventional studies. Of the 81 that completed or were terminated, 21 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 87 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 107th largest by enrollment of the 149 interventional ones that give a count, is one of 14 that started in 2013, is one of 54 in phase 3, and was the 169th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
2 of the studies testing Insulin Aspart in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) with an external continuous subcutaneous insulin infusion (CSII) system in adult subjects with type 1 diabetes.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 37 is close to the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
Drug: Faster-acting insulin aspart
The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
Drug: insulin aspart
Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Number of Microscopically Confirmed Episodes of Infusion Set Occlusions
The number of microscopically confirmed episodes of infusion set occlusions during 6 weeks of treatment. Episodes of infusion set occlusions were confirmed by microscopic examination of the infusion sets at each routine weekly visit and infusion sets that had been changed prematurely because of leakage, unexplained hyperglycaemia or suspicion of occlusion (observation of a plug).
Time frame: During 6 weeks of treatment
Number of Unexplained Episodes of Hyperglycaemia (Confirmed by Self-measured Plasma Glucose (SMPG))
Unexplained hyperglycaemia was defined as a confirmed plasma glucose value ≥ 16.7 mmol/L (300 mg/dL) and was unexplained (i.e., no apparent medical, dietary, insulin dosage or pump failure reason)
Time frame: During 6 weeks of treatment
Number of Episodes of Possible Infusion Set Occlusions
Episodes of possible infusion set occlusions were defined as infusion sets changed due to suspicion of occlusion, leakage or unexplained hyperglycaemic episode. Possible occlusion excluded technical reasons. This endpoint was calculated from the recorded date/times of changes of infusion set combined with the subjects' own assessment.
Time frame: During 6 weeks of treatment
Number of Premature Infusion Set Changes
A premature infusion set change was defined as not being a routine change. This was defined as an infusion set changed at home due to "suspicion of occlusion", "leakage", "unexplained hyperglycaemic episode", "infusion site reaction", "technical reason", or "other". The change of infusion set at a site visit was considered a routine change unless an occlusion was actually suspected at the site.
Time frame: During 6 weeks of treatment
The trial was conducted at two sites in two countries as follows: USA: one site; Germany: one site.
| Milestone | Faster-acting Insulin Aspart | NovoRapid® |
|---|---|---|
| Started | 25 | 12 |
| Completed | 24 | 12 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
The number of microscopically confirmed episodes of infusion set occlusions during 6 weeks of treatment. Episodes of infusion set occlusions were confirmed by microscopic examination of the infusion sets at each routine weekly visit and infusion sets that had been changed prematurely because of leakage, unexplained hyperglycaemia or suspicion of occlusion (observation of a plug).
| Episodes | Faster-acting Insulin Aspart | NovoRapid® |
|---|---|---|
| Number of Microscopically Confirmed Episodes of Infusion Set Occlusions | 0 | 0 |
Unexplained hyperglycaemia was defined as a confirmed plasma glucose value ≥ 16.7 mmol/L (300 mg/dL) and was unexplained (i.e., no apparent medical, dietary, insulin dosage or pump failure reason)
| events | Faster-acting Insulin Aspart | NovoRapid® |
|---|---|---|
| Number of Unexplained Episodes of Hyperglycaemia (Confirmed by Self-measured Plasma Glucose (SMPG)) | 28 | 16 |
Episodes of possible infusion set occlusions were defined as infusion sets changed due to suspicion of occlusion, leakage or unexplained hyperglycaemic episode. Possible occlusion excluded technical reasons. This endpoint was calculated from the recorded date/times of changes of infusion set combined with the subjects' own assessment.
| Episodes | Faster-acting Insulin Aspart | NovoRapid® |
|---|---|---|
| Number of Episodes of Possible Infusion Set Occlusions | 7 | 0 |
A premature infusion set change was defined as not being a routine change. This was defined as an infusion set changed at home due to "suspicion of occlusion", "leakage", "unexplained hyperglycaemic episode", "infusion site reaction", "technical reason", or "other". The change of infusion set at a site visit was considered a routine change unless an occlusion was actually suspected at the site.
| Episodes | Faster-acting Insulin Aspart | NovoRapid® |
|---|---|---|
| Number of Premature Infusion Set Changes | 21 | 4 |
Collected over A treatment emergent adverse event is defined as en event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Faster-acting Insulin Aspart | — | 0/25 (0%) | 9/25 (36%) |
| NovoRapid® | — | 0/12 (0%) | 6/12 (50%) |
| Event | Faster-acting Insulin Aspart | NovoRapid® |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 1/25 | 2/12 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/25 | 2/12 |
| NasopharyngitisInfections and infestations | 3/25 | 1/12 |
| Diabetic retinopathyEye disorders | 0/25 | 1/12 |
| Otitis mediaInfections and infestations | 0/25 | 1/12 |
| PruritusSkin and subcutaneous tissue disorders | 0/25 | 1/12 |
| PyrexiaGeneral disorders | 1/25 | 1/12 |
| RashSkin and subcutaneous tissue disorders | 0/25 | 1/12 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/25 | 1/12 |
| SinusitisInfections and infestations | 0/25 | 1/12 |
Full Analysis Set: included all randomised subjects. In exceptional cases subjects could be excluded from the full analysis set. In such cases the reason for exclusion was to be justified and documented. Safety analysis set: includes all subjects receiving at least one dose of the investigational product or its comparator.
| Age, Continuous(years) | Faster-acting Insulin Aspart | NovoRapid® | Total |
|---|---|---|---|
| Mean | 48.9 ± 14.6 | 34.7 ± 9.1 | 44.3 ± 14.6 |
| Age, Customized(participants) | Faster-acting Insulin Aspart | NovoRapid® | Total |
|---|---|---|---|
| 18-64 | 19 | 12 | 31 |
| 65-84 | 6 | 0 | 6 |
| Sex: Female, Male(Participants) | Faster-acting Insulin Aspart | NovoRapid® | Total |
|---|---|---|---|
| Female | 11 | 4 | 15 |
| Male | 14 | 8 | 22 |
Ran from Nov 2013 to primary completion in May 2014, 5 months.
Results were first posted in Oct 2017, 3 years 5 months after primary completion. A results delay was requested in Nov 2016.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 5 months is below that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Aspart